No article text was recorded for this version.
prime-boost interval optimization
Version 2 of 219 papers29 conceptsfrozen 2026-10-04
Papers in this version
- Blog: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
- Blog: Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
- Blog: Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
- Blog: Immune Persistence against SARS-CoV-2 after Primary and Booster Immunization in Humans: A Large-Scale Prospective Cohort Study
- Blog: Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana
- Blog: A modelling analysis of pertussis transmission and vaccination in Rio de Janeiro, Brazil
- Blog: BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults
- Blog: WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1
- Blog: Optimizing Vaccine Allocation Strategies in Pandemic Outbreaks: An Optimal Control Approach
- Blog: Influenza Vaccine Effectiveness against Influenza A-Associated Outpatient and Emergency-Department-Attended Influenza-like Illness during the Delayed 2022–2023 Season in Beijing, China
- Blog: Efficacy and safety of intralymphatic immunotherapy for allergic rhinitis: an overview of systematic reviews and meta analyses
- Blog: Evaluating the impact of extended dosing intervals on mRNA COVID-19 vaccine effectiveness in adolescents
- Blog: Do immunosuppressive treatments influence immune responses against adenovirus-based COVID-19 vaccines in patients with multiple sclerosis? An Argentine multicenter study
- Blog: Comparative efficacy of experimental inactivated and live-attenuated chimeric porcine circovirus (PCV) 1-2b vaccines derived from PCV1 and PCV2b isolates originated in China
- Blog: Optimal Allocation of Multi-Type Vaccines in a Two-Dose Vaccination Campaign for Epidemic Control: A Case Study of COVID-19
- Blog: Computational Model Reveals a Stochastic Mechanism behind Germinal Center Clonal Bursts
- Blog: COVID-19 mRNA Vaccination: Age and Immune Status and Its Association with Axillary Lymph Node PET/CT Uptake
- Blog: Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination
- Blog: Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis
History & citation
Current · Permanent link
Cite this direction
Latest version (a living page):
@misc{lacuna_prime_boost_interval_optimization_4db59dc1,
title = {prime-boost interval optimization},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/prime-boost-interval-optimization/rdr_4db59dc1bf6d4acb8ed66e8d5f3317f4},
note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}This exact version (version 2, frozen text):
@misc{lacuna_prime_boost_interval_optimization_4db59dc1_v2,
title = {prime-boost interval optimization},
author = {{Lacuna}},
howpublished = {Lacuna research direction},
year = {2026},
url = {https://lacuna.tiptreesystems.com/direction/prime-boost-interval-optimization/rdr_4db59dc1bf6d4acb8ed66e8d5f3317f4/v/2},
note = {Version 2, frozen 2026-10-04. Accessed 2026-11-20},
}